Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some major FDA-labeled indication statements are supported, and mechanism language is largely consistent with the label’s suggested mechanism. However, multiple patient-assistance/savings program claims (amounts, eligibility criteria, Medicare use) are not supported by the provided FDA prescribing information and therefore substantially limit alignment.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Indications and Usage: adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Vascepa is used to reduce the risk of cardiovascular events in adults with established cardiovascular disease or diabetes.
Indications and Usage: adjunct to maximally tolerated statin therapy to reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG (≥150 mg/dL) and established CVD or diabetes mellitus and 2+ additional risk factors for CVD.
Vascepa works by inhibiting the production of triglycerides in the liver.
Mechanism of Action (12.1): studies suggest EPA reduces hepatic VLDL-TG synthesis and/or secretion and enhances TG clearance.
Unsupported Statements
The Vascepa Savings Card offers a maximum savings of $100 per month, with a maximum annual savings of $1,200.
No savings-card amount/maximums are provided in the supplied FDA prescribing information.
The Vascepa Patient Assistance Program provides free Vascepa to eligible patients who cannot afford the medication.
No patient assistance program existence, eligibility, or 'free' terms are provided in the supplied FDA prescribing information.
The manufacturer's coupon offers a $100 discount on Vascepa prescriptions.
No coupon/discount amount is provided in the supplied FDA prescribing information.
For most Vascepa savings programs, patients must be at least 18 years old to qualify.
No program-specific age eligibility criteria are provided in the supplied FDA prescribing information.
To qualify for the Vascepa Patient Assistance Program, patients must have household income at or below 200% of the federal poverty level.
No income-based eligibility criteria are provided in the supplied FDA prescribing information.
For most Vascepa savings programs, patients must have commercial insurance or be uninsured to qualify.
No payer/insurance-type eligibility criteria are provided in the supplied FDA prescribing information.
To qualify for Vascepa, patients must have a diagnosis of severe hypertriglyceridemia or cardiovascular disease.
Label indications specify additional criteria (elevated TG thresholds, adjunct context, and for cardiovascular risk: diabetes plus 2+ additional risk factors, and elevated TG ≥150 mg/dL). The claim is not supported as a complete/general qualification statement.
Patients with Medicare can use the Vascepa Savings Card to save on their Vascepa prescriptions.
No Medicare eligibility statements for savings cards are provided in the supplied FDA prescribing information.
Contradictions
Important Omissions
When claiming cardiovascular-event risk reduction, the label requires additional qualifiers (adult patients with elevated TG ≥150 mg/dL and established CVD OR diabetes mellitus plus 2 or more additional risk factors; and as an adjunct to maximally tolerated statin therapy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported/likely inaccurate patient-assistance/savings details could mislead patients about access/eligibility. The FDA-labeled medical indication statements are largely supported, but cardiovascular indication wording omits label-required qualifiers.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple savings/program amount and eligibility claims are not supported by the provided FDA prescribing information.
Suggested Improvement
Limit statements about assistance/savings to what is explicitly supported by FDA labeling provided, and for indications include label qualifiers (adjunct to maximally tolerated statin therapy; elevated TG thresholds and diabetes/additional risk factors as applicable).